Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Rating) have been assigned an average recommendation of “Buy” from the seven analysts that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $48.33.
Several brokerages recently weighed in on REPL. JPMorgan Chase & Co. lowered their price objective on Replimune Group from $47.00 to $39.00 and set an “overweight” rating for the company in a report on Monday, April 4th. Zacks Investment Research lowered Replimune Group from a “hold” rating to a “sell” rating in a report on Wednesday. BMO Capital Markets lowered their price objective on Replimune Group from $51.00 to $30.00 and set an “outperform” rating for the company in a report on Friday, March 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Replimune Group in a report on Tuesday, January 11th.
In other news, major shareholder Fund Iv L.P. Omega sold 16,500 shares of the company’s stock in a transaction that occurred on Monday, March 14th. The stock was sold at an average price of $15.42, for a total transaction of $254,430.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 40.30% of the stock is currently owned by corporate insiders.
NASDAQ:REPL opened at $17.76 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 23.39 and a current ratio of 23.39. Replimune Group has a one year low of $14.98 and a one year high of $40.22. The business’s 50-day simple moving average is $17.00 and its 200 day simple moving average is $24.23. The stock has a market cap of $838.45 million, a price-to-earnings ratio of -8.58 and a beta of 2.45.
Replimune Group (NASDAQ:REPL – Get Rating) last released its quarterly earnings results on Thursday, February 3rd. The company reported ($0.57) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.58) by $0.01. On average, equities research analysts predict that Replimune Group will post -2.26 EPS for the current year.
About Replimune Group (Get Rating)
Replimune Group, Inc, a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma.
- Get a free copy of the StockNews.com research report on Replimune Group (REPL)
- Array Technologies Stock Giving Another Ground Floor Entry
- UiPath Stock is Nearing Rock Bottom Down Here
- 3 Undervalued S&P 500 Stocks to Buy Now
- 3 Undervalued Easter Eggs to Watch For This Earnings Season
- Lululemon Rises On Wave Of Price Target Increases
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.